Killing of Tumor Cells with Pleiotropic Drug Resistance by OK432-Activated Effector Cells
- 1 January 1989
- journal article
- research article
- Published by Taylor & Francis in Immunopharmacology and Immunotoxicology
- Vol. 11 (2-3) , 257-268
- https://doi.org/10.3109/08923978909005369
Abstract
The inactivated streptococcal preparation OK432 activates the cytotoxic function of natural killer (NK) cells. Moreover, it induces cytotoxic activity against freshly isolated tumor cells. The present study was aimed at assessing whether OK432-activated effector cells expressed cytotoxicity against tumor cell pleiotropically resistant to cancer chemotherapy agents. OK432-treated lymphoid cells killed the multidrug resistant (MDR) LOVO DX line as efficiently as drug sensitive parental LOVO N carcinoma line. Effector cells involved in killing MDR cells were low density large granular lymphocytes with NK functions. Activation of effector cells has the potential to complement conventional cytoreductive therapy by eliminating residual tumor cells surviving and resistant to chemotherapy.This publication has 16 references indexed in Scilit:
- The cell biology of multiple drug resistanceBiochemical Pharmacology, 1987
- Human tumor cell lines with pleiotropic drug resistance are efficiently killed by interleukin‐2 activated killer cells and by activated monocytesInternational Journal of Cancer, 1987
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Lymphokine-activated killer cells. Analysis of progenitors and effectors.The Journal of Experimental Medicine, 1986
- Isolation and characterization of a human colon adenocarcinoma cell line resistant to doxorubicinBritish Journal of Cancer, 1986
- Effect of a streptococcal preparation (OK432) on natural killer activity of tumour-associated lymphoid cells in human ovarian carcinoma and on lysis of fresh ovarian tumour cellsBritish Journal of Cancer, 1983
- AUGMENTATION OF NK CELL ACTIVITY IN CANCER PATIENTS BY 0K432: ACTIVATION OF NK CELLS AND REDUCTION OF SUPPRESSOR CELLSPublished by Elsevier ,1982
- In vitro augmentation of natural killing activity by OK-432International Journal of Immunopharmacology, 1981
- Reduction of suppressor cells in cancer patients treated with OK-432 immunotherapyInternational Journal of Cancer, 1980
- Clinical studies on cell-mediated immunity in patients with malignant disease I. Effect of immunotherapy with OK-432 on lymphocyte subpopulation and phytomitogen responsivenessin vitroCancer, 1980